[Cisplatin-based chemotherapy in muscle-invasive bladder cancer: soon outdated ?]

Bosshard, Piet; Roth, Beat (2019). [Cisplatin-based chemotherapy in muscle-invasive bladder cancer: soon outdated ?]. Revue médicale suisse, 15(673), pp. 2190-2194. Médecine & Hygiène

[img] Text
Ro_Chimiotherapie neoadjuvante a base.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (256kB) | Request a copy

For more than 30 years, cisplatin-based neoadjuvant chemotherapy (NAC) has been administered to patients with muscle-invasive bladder cancer (MIBC). However, the benefit is modest. With the advent of modern immunotherapies, new therapeutic strategies are also opening up to bladder cancer. Unfortunately, the initial results in the neoadjuvant context show a response rate of only 20-35 %. Other therapeutic strategies, such as Pan-FGFR inhibitors, do not show better response. Due to the high genetic variability of bladder cancer, a « one drug fits all » concept is not an ideal solution. Patient selection based on the probability of response appears to be a promising strategy to improve this modest benefit of each treatment. In this context, the NAC will also continue to play an important role.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Bosshard, Piet and Roth, Beat

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0025-6749

Publisher:

Médecine & Hygiène

Language:

French

Submitter:

Jeannine Wiemann

Date Deposited:

03 Feb 2020 08:57

Last Modified:

03 Feb 2020 08:57

PubMed ID:

31778047

BORIS DOI:

10.7892/boris.138024

URI:

https://boris.unibe.ch/id/eprint/138024

Actions (login required)

Edit item Edit item
Provide Feedback